Verrica Pharmaceuticals Q3 2025 Earnings Report

Verrica Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.14
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Verrica Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $8.34 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Verrica Pharmaceuticals Announcement Details

• Quarter: Q3 2025
• Date: 11/3/2025
• Time: Before Market Opens
• Conference Call Date: Monday, November 3, 2025
• Conference Call Time: 9:30AM ET

Verrica Pharmaceuticals (NASDAQ:VRCA) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions. The company conducts its clinical trials primarily in the United States and has engaged with regulatory authorities in Europe to support potential future filings. Verrica collaborates with contract research organizations and academic partners to execute its development programs and gather data on safety and efficacy.

Founded in 2020 as a strategic spin-out from Aclaris Therapeutics, Verrica is headquartered in West Chester, Pennsylvania. The company’s management team brings deep expertise in dermatology drug development, clinical operations and commercial strategy. As Verrica moves toward potential product approvals, it aims to address significant unmet needs in pediatric and adult dermatology markets.